Ito M, Miyake M, Mitsuoka A
Gan To Kagaku Ryoho. 1985 Jul;12(7):1361-70.
Among anterior mediastinal tumors affecting male patients of around 20 years old, mediastinal malignant teratoid tumor must be considered as one of the possibilities. Malignant teratoid tumor can be classified as seminoma, non-seminoma or mixed, according to clinical behavior. In the non-seminoma group, AFP and/or HCG can be the specific markers in the diagnosis or assessment of the effect of treatment. Chemotherapy with CDDP must be the first choice of treatment in these types of tumor, just as chemotherapy is the first choice of therapy in the treatment of small cell lung cancer, and surgery must be the adjuvant treatment to chemotherapy. On the other hand, seminoma can be treated by surgery and radiation, which has been proven to yield a good prognosis. In cases of seminoma which produces HCG and/or AFP, chemotherapy with CDDP must be added to surgery and radiation as in non-seminomatous mediastinal teratoid tumors, because the production of such markers in seminoma is considered to be one of the poor prognostic factors in the treatment of seminomatous mediastinal teratoid tumors.
在影响20岁左右男性患者的前纵隔肿瘤中，纵隔恶性畸胎瘤必须被视为可能的病因之一。根据临床行为，恶性畸胎瘤可分为精原细胞瘤、非精原细胞瘤或混合型。在非精原细胞瘤组中，甲胎蛋白（AFP）和/或人绒毛膜促性腺激素（HCG）可作为诊断或评估治疗效果的特异性标志物。对于这类肿瘤，顺铂化疗必须是首选治疗方法，就像化疗是小细胞肺癌治疗的首选疗法一样，手术必须作为化疗的辅助治疗。另一方面，精原细胞瘤可通过手术和放疗进行治疗，这已被证明能产生良好的预后。在产生HCG和/或AFP的精原细胞瘤病例中，与非精原性纵隔畸胎瘤一样，在手术和放疗的基础上必须加入顺铂化疗，因为在精原性纵隔畸胎瘤的治疗中，此类标志物的产生被认为是不良预后因素之一。
